Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Tomelleri

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Seminars in Arthritis and Rheumatism|February 17, 2026
Definitions and online reliability assessment of elementary ultrasound lesions in Takayasu arteritis: a study from the OMERACT Ultrasound Working GroupAlessandro Tomelleri, Simon J Reider, Christian Dejaco, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 11, 2025
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert PanelArsene M Mekinian, Sophie Georgin-Lavaille, Marcela A Ferrada, et al.
Seminars in Arthritis and Rheumatism|January 31, 2026
VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registriesFrancesco Gavioli, Valeria Caggiano, Jessica Sbalchiero, et al.
Frontiers in Medicine|December 27, 2023
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's DiseaseAntonio Vitale, Valeria Caggiano, Petros P Sfikakis, et al.
Seminars in Arthritis and Rheumatism|March 30, 2024
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registryAntonio Vitale, Valeria Caggiano, Eduardo Martin-Nares, et al.
Frontiers in Pharmacology|March 6, 2025
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryAntonio Vitale, Valeria Caggiano, Flavia Leone, et al.
Frontiers in Pharmacology|March 24, 2025
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA networkAntonio Vitale, Flavia Leone, Valeria Caggiano, et al.
RMD Open|December 6, 2023
Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registryAntonio Vitale, Valeria Caggiano, Giuseppe Lopalco, et al.
Seminars in Arthritis and Rheumatism|July 30, 2023
The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease RegistryPiero Ruscitti, Jurgen Sota, Antonio Vitale, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 19, 2024
The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease RegistryPiero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Seminars in Arthritis and Rheumatism|February 17, 2026
Definitions and online reliability assessment of elementary ultrasound lesions in Takayasu arteritis: a study from the OMERACT Ultrasound Working GroupAlessandro Tomelleri, Simon J Reider, Christian Dejaco, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 11, 2025
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert PanelArsene M Mekinian, Sophie Georgin-Lavaille, Marcela A Ferrada, et al.
Seminars in Arthritis and Rheumatism|January 31, 2026
VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registriesFrancesco Gavioli, Valeria Caggiano, Jessica Sbalchiero, et al.
Frontiers in Medicine|December 27, 2023
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's DiseaseAntonio Vitale, Valeria Caggiano, Petros P Sfikakis, et al.
Seminars in Arthritis and Rheumatism|March 30, 2024
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registryAntonio Vitale, Valeria Caggiano, Eduardo Martin-Nares, et al.
Frontiers in Pharmacology|March 6, 2025
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryAntonio Vitale, Valeria Caggiano, Flavia Leone, et al.
Frontiers in Pharmacology|March 24, 2025
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA networkAntonio Vitale, Flavia Leone, Valeria Caggiano, et al.
RMD Open|December 6, 2023
Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registryAntonio Vitale, Valeria Caggiano, Giuseppe Lopalco, et al.
Seminars in Arthritis and Rheumatism|July 30, 2023
The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease RegistryPiero Ruscitti, Jurgen Sota, Antonio Vitale, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 19, 2024
The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease RegistryPiero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
Pageof 13